- Home
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Club
- Mobile
- Trust Equitymaster
- Help
- Free Reports
-
Mobile App
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- SUN PHARMA - TEVA PHARMA (Israel)
SUN PHARMA vs TEVA PHARMA (Israel) - Comparison Results
SUN PHARMA 
Change
Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More
TEVA PHARMA (Israel)
Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
Financials
 SUN PHARMA  TEVA PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| SUN PHARMA Mar-17 |
TEVA PHARMA Dec-13 |
SUN PHARMA/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 842 | 2,685 | - | |
| Low | Rs | 572 | 2,333 | - | |
| Sales per share (Unadj.) | Rs | 131.6 | 1,541.0 | - | |
| Earnings per share (Unadj.) | Rs | 32.7 | 96.3 | - | |
| Cash flow per share (Unadj.) | Rs | 38.0 | 220.8 | - | |
| Dividends per share (Unadj.) | Rs | 3.50 | 84.27 | - | |
| Dividend yield (eoy) | % | 0.5 | 3.4 | 14.7% | |
| Book value per share (Unadj.) | Rs | 152.7 | 1,711.8 | - | |
| Shares outstanding (eoy) | m | 2,399.26 | 848.00 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 5.4 | 1.6 | 330.1% | |
| Avg P/E ratio | x | 21.6 | 26.1 | 83.0% | |
| P/CF ratio (eoy) | x | 18.6 | 11.4 | 163.9% | |
| Price / Book Value ratio | x | 4.6 | 1.5 | 316.0% | |
| Dividend payout | % | 10.7 | 87.5 | 12.2% | |
| Avg Mkt Cap | Rs m | 1,696,877 | 2,127,522 | 79.8% | |
| No. of employees | `000 | 17.5 | 44.9 | 39.0% | |
| Total wages/salary | Rs m | 49,023 | 0 | - | |
| Avg. sales/employee | Rs Th | 18,028.3 | 29,075.5 | 62.0% | |
| Avg. wages/employee | Rs Th | 2,798.8 | 0 | - | |
| Avg. net profit/employee | Rs Th | 4,479.5 | 1,816.3 | 246.6% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 315,784 | 1,306,800 | 24.2% | |
| Other income | Rs m | 6,232 | 0 | - | |
| Total revenues | Rs m | 322,016 | 1,306,800 | 24.6% | |
| Gross profit | Rs m | 100,893 | 357,868 | 28.2% | |
| Depreciation | Rs m | 12,648 | 105,630 | 12.0% | |
| Interest | Rs m | 3,998 | 25,668 | 15.6% | |
| Profit before tax | Rs m | 90,479 | 226,570 | 39.9% | |
| Minority Interest | Rs m | 0 | 1,029 | 0.0% | |
| Prior Period Items | Rs m | 99 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | -148,731 | 0.0% | |
| Tax | Rs m | 12,116 | -2,766 | -438.0% | |
| Profit after tax | Rs m | 78,462 | 81,635 | 96.1% | |
| Gross profit margin | % | 31.9 | 27.4 | 116.7% | |
| Effective tax rate | % | 13.4 | -1.2 | -1,096.8% | |
| Net profit margin | % | 24.8 | 6.2 | 397.7% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 329,537 | 882,608 | 37.3% | |
| Current liabilities | Rs m | 178,870 | 769,708 | 23.2% | |
| Net working cap to sales | % | 47.7 | 8.6 | 552.3% | |
| Current ratio | x | 1.8 | 1.1 | 160.7% | |
| Inventory Days | Days | 79 | 91 | 87.0% | |
| Debtors Days | Days | 83 | 96 | 86.8% | |
| Net fixed assets | Rs m | 204,766 | 426,830 | 48.0% | |
| Share capital | Rs m | 2,399 | 3,217 | 74.6% | |
| Net worth | Rs m | 366,397 | 1,451,606 | 25.2% | |
| Long term debt | Rs m | 14,361 | 668,196 | 2.1% | |
| Total assets | Rs m | 614,102 | 2,986,456 | 20.6% | |
| Interest coverage | x | 23.6 | 9.8 | 240.5% | |
| Debt to equity ratio | x | 0 | 0.5 | 8.5% | |
| Sales to assets ratio | x | 0.5 | 0.4 | 117.5% | |
| Return on assets | % | 13.4 | 3.6 | 373.7% | |
| Return on equity | % | 21.4 | 5.6 | 380.8% | |
| Return on capital | % | 24.8 | 4.9 | 503.7% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 70,822 | 208,236 | 34.0% | |
| From Investments | Rs m | -42,216 | -73,787 | 57.2% | |
| From Financial Activity | Rs m | -22,854 | -249,793 | 9.1% | |
| Net Cashflow | Rs m | 6,107 | -115,344 | -5.3% | |
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 64.33 Rs / USD
Compare SUN PHARMA With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US)
Compare SUN PHARMA With: ABBOTT INDIA FDC LTD. BIOCON LTD SANOFI INDIA ORCHID PHARMA LTD
|
| |
Today's Market
Share Markets in India End Flat; Dr Reddy's & Tata Steel Top Gainers(Closing)
Indian share markets continued to trade range bound in afternoon session with market participants awaiting the US Federal Reserve's policy statement.
Related Views On News
Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)
Aug 14, 2017A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.
Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)
May 30, 2017US markets decline while other geographies grow in the quarter.
Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)
Mar 11, 2017Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.
Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)
Aug 14, 2017GST impact coupled with price erosion in US leads to lower profits for the quarter.
Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)
Aug 8, 2017Profits plunge due to higher raw material costs.
More Views on NewsMost Popular
India's Big and Messy Real Estate Ponzi Scheme, Just Got Messier(Vivek Kaul's Diary)
Sep 11, 2017The question is, whether real estate buyers are financial creditors or not.
180,000%: The Returns That Could Have Been(The 5 Minute Wrapup)
Sep 7, 2017For successful investing in small caps, it's important to know when not to press the panic button.
Feeling Left Out? Two Opportunities to Make Money in This Market(Daily Profit Hunter)
Sep 13, 2017Nifty is above 10,000 once again. Have you missed the bus?
Introducing Smart Contrarian: The Blueprint for Big Profits from Small Investments
Sep 18, 2017Welcome to a bold, new initiative designed for the truly contrarian investor.
How To Link Aadhaar With Your Mutual Fund Investments(Outside View)
Sep 11, 2017The Government has extended the linking of the unique Aadhaar number to nearly all financial transactions.
More|
| |
SUN PHARMA SHARE PRICE
Sep 20, 2017 (Close)
TRACK SUN PHARMA
- Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON SUN PHARMA
SUN PHARMA - FULFORD INDIA COMPARISON
COMPARE SUN PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | Advertise | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
